We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...
AN OPPORTUNITY FOR $800K IN SEED FUNDING
WHO?
•
Medical device start-ups
•
MDs
•
Entrepreneurs
WHAT?
The 2020 Vascular Challenge by MEDX Xelerator focuses on two domains of innovation: peripheral interventions (PI) and disruptive neurovascular technologies.
WHEN?
Application Deadline:
Monday, November 30, 2020
THE TWO ROUTES OF MEDX S’XELERATOR 2020 VASCULAR CHALLENGE
•
Technology: An early-stage company looking for a seed round of ~$800K operating in the field of peripheral interventions or neurovascular. MEDX is open to reviewing technologies that already implemented a prototype with proof of concept or are just an idea looking for feasibility testing. We are generally also open to ventures that are either formed as companies or not yet. The technology may be an established technology from another field redirected to peripheral interventions or neurovascular, an improvement over existing technologies or a new technology.
•
Unmet Clinical needs: Typically an MD or entrepreneur identifying a strong clinical need within the field of peripheral interventions & neurovascular without a solution.
About MEDX Xelerator
MEDX Xelerator is a leading MedTech incubator – a partnership of Boston Scientific, Sheba Medical Center and MEDX Ventures. Operating under the auspices of the Israel Innovation Authority, MEDX leverages the healthcare expertise and industry experience of its team with the industry leading insights of its partners to identify and nurture high impact medical ventures for the benefit of patients and health care professionals. MEDX’s portfolio companies all address major clinical needs with significant innovation in big markets and the incubator team works closely with the teams to consistently achieve outstanding clinical and business goals in capital efficient way. The incubation program is a 2-years program with $800K in seed funding and access to a strong network, of Key Opinion Leaders and supports all aspects of the ventures including business
development, multi-disciplinary R&D, IP consultation, marketing and PR services, accounting and administrative office services. All companies operate from the incubator office space -a vibrant environment of innovation and a company culture that supports focus and goal achievement. The incubator is open to innovation coming from
either Israel or international entrepreneurs, universities and hospitals.
Vascular Diseases
Non-cardiac vascular diseases are a major cause of disability. Common vascular diseases include atherosclerosis, stroke, blood clots, peripheral artery disease, aneurysms, hypertension, and pulmonary embolisms. Vascular diseases can cause blocked or narrowed arteries and veins in the neck, arms, legs and abdomen (peripheral vessels in areas other than the heart). Peripheral vascular intervention procedures are used to open blocked arteries and veins.
Interventional radiologists use medical tools such as guidewires, catheters and ablation tools along with imaging modalities like fluoroscopy, ultrasound, computed tomography, and magnetic resonance imaging to repair blockages in the peripheral blood vessels.
Suggested Vascular Development Directions:
•
Create a disruptive and new technology for intravascular imaging
•
Novel solutions for deep venous disease (e.g., occlusions, incompetent valves) to treat chronic venous insufficiency
•
Make existing vascular disease procedures more effective or create new procedures
•
Steerable/deflectable guidewires/microcatheters
•
Chronic Total Occlusion (CTO) tools
•
Venous access devices
•
Closure devices
•
Smart guidewires (force sensing)
•
Vascular image processing
Neurovascular Diseases
Neurovascular diseases are a leading cause of adult disabilities and death. Neurovascular diseases include abnormalities of the blood vessels supplying the brain and spine such as arteries narrowing and arteries weakening. Common neurovascular diseases are stroke, brain aneurysm, carotid stenosis, venous sinus thrombosis, cerebral cavernous malformation, intracranial vascular disease, and Moyamoya disease.
Suggested Neurovascular Development Directions:
•
Disruptive opportunities within the broader neurovascular space
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."
This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.
“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”
